Ryan Marotta, Assistant Editor

Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.

Teva Pharmaceutical Industries recently announced that the FDA has accepted for review a New Drug Application for its investigational formulation of extended-release hydrocodone bitartrate with abuse-deterrent properties.

Lilly and Incyte have recently announced positive results from the second phase 3 study of their investigational drug baricitinib, a potential treatment for rheumatoid arthritis.

The FDA recently granted priority review to Novarits' investigational drug LCZ696, a potential treatment for heart failure with ejection fraction.

Panobinostat found to reduce cancer in 59% of participants compared with 41% treated with bortezomib and dexamethasone.

The FDA today approved Novartis Pharmaceuticals' panobinostat (Farydak) for the treatment of patients with multiple myeloma who have received at least 2 prior standard therapies.

Antismoking advocates have much to celebrate.

Teva Pharmaceutical Industries recently launched generic versions of Sanofi's enoxaparin sodium injection (Lovenox) and Pfizer's linezolid injection (Zyvox).

The FDA today approved Sapheon's VenaSeal closure system, the first device developed to permanently treat varicose veins of the legs by using an adhesive agent to seal the affected superficial veins.

Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.

Galderma Laboratories has announced the US launch of its ivermectin 1% cream (Soolantra), a topical treatment for rosacea.

Patients experienced a 95% reduction in median annualized bleed rate.

Lightlake Therapeutics recently announced that the FDA has granted Fast Track designation to Adapt Pharma's intranasal naloxone, an opioid overdose reversal agent.

As a pharmacy student at the Virginia Commonwealth University School of Pharmacy, Kalyann Kauv has demonstrated a passion for serving patients across cultural and social boundaries.

Baxter International recently revealed new data from a phase 3 pivotal study of its investigational drug, BAX 855, an extended half-life recombinant factor VIII treatment for hemophilia A.

The FDA recently accepted for review New Drug Applications for Collegium Pharmaceuticals' extended-release oxycodone formulation (Xtampza ER) and Pfizer's extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair of opioid analgesics with abuse-deterrent properties.

While national recommendations on fat consumption might have influenced patients' dietary habits, a new study found insufficient evidence to support those guidelines.

As the roles and responsibilities of pharmacists continue to evolve, perhaps no endeavor is more important to the profession than that of health care provider status.

Lenvima-treated patients experienced a median of 18.3 progression-free months.

The FDA today approved a supplemental New Drug Application for Eisai's rufinamide (Banzel) as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome in pediatric patients aged 1 to 4 years.

The FDA today approved Eisai's kinase inhibitor, lenvatinib (Lenvima), for the treatment of differentiated thyroid cancer in patients whose disease progressed despite receiving radioactive iodine therapy.

Hospira is voluntarily recalling 63 lots of its ketorolac tromethamine injection following a confirmed report of calcium-ketorolac crystals floating in glass vials of the product.

The FDA has accepted for review a New Drug Application for Inspirion Delivery Technologies' investigational opioid analgesic, MorphaBond ER, an abuse-deterrent formulation of extended-release morphine.

The FDA has granted 510(k) clearance to Silk Road Medical's Enroute Transcarotid Neuroprotection System (TNS), a first-in-class device to restore normal blood flow to narrowed carotid arteries during carotid angioplasty and stenting.

Daiichi Sankyo today announced the US launch of edoxaban, a once-daily anti-clotting agent indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Amidst a number of recent norovirus outbreaks, a study has determined that the disinfecting capabilities of cold atmospheric pressure plasma may prove useful in reducing the spread of the virus.

Disease scores with biosimilar equivalent to those who received reference product.

Expanded indication would include patients with relapsed multiple myeloma who received prior therapy.

Actavis recently announced that its supplemental New Drug Application to expand the label of its antibacterial drug, ceftaroline-fosamil, has been accepted for filing by the FDA.

The FDA today expanded the indication of Roche's ranibizumab (Lucentis), approving the drug for the treatment of diabetic retinopathy in patients with diabetic macular edema.